Overview

Neratinib, development code HKI-272 and marketed as Hernix, is an irreversible pan-HER tyrosine kinase inhibitor supplied as 40 mg tablets in a 180-table pack. Its defining role is in the extended adjuvant setting for HER2-positive early breast cancer, where it is used after trastuzumab-based therapy to reduce recurrence risk. The combination angle is central: neratinib is almost never discussed in isolation, because its value is defined by how it extends and complements earlier HER2 blockade.

How It Works

Neratinib covalently binds and irreversibly inhibits the HER1, HER2, and HER4 receptors, blocking downstream MAPK and PI3K/AKT signaling that drives HER2-amplified cell growth. The irreversible covalent bond gives sustained target suppression compared with reversible inhibitors. In the extended adjuvant context the aim is to eliminate residual HER2-driven clones that survive initial therapy. Combination thinking matters because neratinib is layered on top of, rather than instead of, prior trastuzumab-based treatment.

Indications

Neratinib is indicated for adults with early-stage HER2-positive breast cancer as extended adjuvant therapy following completion of trastuzumab-based treatment. Selection follows the registered adjuvant label and prior treatment history. B2B listings should reflect the approved scope of each market and avoid suggesting use outside the adjuvant setting.

Dosage & Administration

Presented as 40 mg tablets in a 180-table pack sized for the extended adjuvant course. Administration follows the locally approved labeling, typically taken daily with food, with anti-diarrheal prophylaxis managed by the treating team. Pack and batch details are printed for traceability. Store as labeled, protected from moisture.

Storage & Sourcing

Manufactured under GMP by Pierre Fabre, DIL, and Beacon partners, neratinib ships with COA and GMP documents. Temperature-controlled guidance supports export stability. MOQ and lead time are per contract, and the supplier provides oncology import documentation. Distributors should also brief procurement teams on the standard diarrhea-management plan, since supportive care forms part of the total cost of therapy. Buyers comparing pan-HER agents should weigh pack size and course duration together when modeling annual spend.

FAQ

Q: Why is neratinib used as extended adjuvant rather than upfront therapy?
A: It is layered after trastuzumab-based treatment to suppress residual HER2-positive clones and lower late recurrence risk in early breast cancer.

Q: What makes neratinib a combination-oriented agent?
A: Its benefit is defined by extending prior HER2 blockade rather than replacing it, so it is positioned within a sequenced, multi-agent treatment plan.

Q: Which partners supply the 40mg*180 presentation?
A: The 40 mg*180 tablet pack is offered through Pierre Fabre, DIL, and Beacon, with GMP and COA documentation per shipment.